Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179600 | 1.00 | CTSV (0.47) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL24710291 | 1.00 | CTSV (0.47) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL24710009 | 0.94 | CTSV (0.52) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL29179614 | 0.94 | CTSV (0.52) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL29179615 | 0.94 | CTSV (0.52) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL24754688 | 0.87 | CTSS (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL24754687 | 0.87 | CTSS (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL24582659 | 0.86 | CTSS (0.39) | CTSSCTSK | |
| SCHEMBL24754878 | 0.86 | CTSS (0.39) | CTSSCTSK | |
| SCHEMBL21786579 | 0.85 | CTSS (0.41) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | CTSV 39/4885CTSL 19/4885CTSB 15/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | CTSV 39/4885CTSL 19/4885CTSB 15/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | CTSV 39/4885CTSL 19/4885CTSB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.